CJ Cheiljedang, South Korea’s largest food and beverage conglomerate, is set to buy Batavia Biosciences, a Dutch bio firm for $226 million or about €195 million. It was reported that the deal came not long after the company revealed its $8.5 billion growth plan for its four major business areas.
CJ Cheiljedang which is a subsidiary of CJ Group announced on Monday, Nov. 8, that it will be acquiring the said Dutch biotech company as part of its plan to broaden its presence in the contract biopharmaceutical production market.
According to The Korea Economic Daily, the company’s board of directors already gave the “go” signal for the acquisition of 75.8% share in Batavia Biosciences. It was reportedly posted in the regulatory filing that this deal is worth ₩267.7 billion or $226 million.
Moreover, CJ Cheiljedang shared it will buy 50,807 shares in the Leiden, Netherlands-headquartered biotech firm and this includes 13,007 new shares at €3,844 per share. It should be noted that the companies’ acquisition deal is still subject to approval by regulatory authorities in South Korea and the Netherlands.
Once the transactions are complete, CJ will immediately work on the expansion of its “red bio” business which refers to the line of work in the medical and pharmaceutical fields. “There’s no dominant leader in the gene therapy treatment market,” an official at CJ said in a statement. “We want to grow big in this area as soon as possible.”
Batavia Biosciences is based in the Netherlands but is has research and development (R&D) centers and sales offices in Hong Kong and Boston, U.S.A. It was founded by the researchers of Janssen Pharmaceuticals in 2010 and mainly worked on cell and gene therapies under CDMO or Contract Development and Manufacturing Organization program. It has extensive experience in virus vaccine, viral vector, monoclonal antibody, microbial vaccine, and recombinant protein development.
Finally, BioPharma reported that with its acquisition of Batavia Biosciences, it appears that CJ Group is directing its attention back to its pharmaceutical business. After unloading its healthcare unit to Kolmar Korea in 2018, CJ seems to have revived its interest in expanding in the biopharma line.


Samsung Electronics Stock Poised for $1 Trillion Valuation Amid AI and Memory Boom
Flare, Xaman Roll Out One-Click DeFi Vault for XRP Yield via XRPL Wallets
Australian Job Advertisements Hit 16-Month High as Labour Market Stays Resilient
Trump Warns Iran as Gulf Conflict Disrupts Oil Markets and Global Trade
ASX CEO Exit Signals Turbulent Transition Amid Lawsuit and Regulatory Scrutiny
Wall Street Futures Tumble as U.S.-Iran Conflict Escalates and Oil Prices Surge
Strait of Hormuz Oil and LNG Shipments Disrupted After U.S.-Israel Strikes on Iran
Lynas Rare Earths Shares Surge 7% After Malaysia Renews Processing Plant Licence for 10 Years
Coupang Reports Q4 Loss After Data Breach, Revenue Misses Estimates
Germany and China Reaffirm Open Trade and Strategic Partnership in Landmark Beijing Visit
Asian Currencies Slide as US-Israel Strikes on Iran Trigger Oil Surge and Risk-Off Rally
Australia Housing Market Hits Record High Despite RBA Rate Hike
OpenAI Pentagon AI Contract Adds Safeguards Amid Anthropic Dispute
Nvidia to Launch New AI Inference Processor to Boost OpenAI Performance
Japan Manufacturing PMI Jumps to Four-Year High as Global Demand Strengthens
Dominican Republic Unveils Massive Rare Earth Deposits to Boost High-Tech and Energy Sectors
Trump Media Weighs Truth Social Spin-Off Amid $6B Fusion Energy Pivot 



